Showing results (421-430 of 487) with videos related to

Sort By:
Pageof 49
Archives of Internal Medicine|August 1, 1992
Optimal therapeutic level of heparin therapy in patients with venous thrombosisR D Hull, G E Raskob, D Rosenbloom, et al.
Human Molecular Genetics|May 1, 2015
The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteinsMark S Moehle, João Paulo Lima Daher, Travis D Hull, et al.
Archives of Internal Medicine|July 25, 2000
Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial InvestigatorsR D Hull, G F Pineo, C Francis, et al.
Archives of Internal Medicine|February 10, 1997
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspectiveR D Hull, G E Raskob, D Rosenbloom, et al.
The New England Journal of Medicine|October 30, 1986
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosisR D Hull, G E Raskob, J Hirsh, et al.
The American Journal of Medicine|January 9, 2007
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harmsRussell D Hull, Graham F Pineo, Rollin F Brant, et al.
The American Journal of Medicine|December 6, 2006
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancerRussell D Hull, Graham F Pineo, Rollin F Brant, et al.
Annals of Internal Medicine|January 1, 1985
Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis. A randomized trialR D Hull, J Hirsh, C J Carter, et al.
American Journal of Industrial Medicine|March 26, 1998
Immunologic findings among lead-exposed workersL E Pinkerton, R E Biagini, E M Ward, et al.
Lancet (London, England)|March 7, 1987
Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic strokeA G Turpie, M N Levine, J Hirsh, et al.
Pageof 49